June 21, 2010 - Zydus Cadila, a global healthcare provider and one of India’s leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, antidiabetic molecule.The new class of anti-diabetic drugs called Glucagon Like Peptide-1 (GLP -1) agonists came to the fore in May 2005 when the first molecule of this class was approved by the USFDA. Glucagon Like Peptide-1 agonists are being used to treat people with type 2 diabetes who have not been able to control their blood sugar levels with oral medicines. It is an injectible which acts like the natural hormones in the body that lowers blood sugar.
ZYOG1 would represent a next generation GLP-1 agents, as it would not have to be injected but can be taken orally. ZYOG1, when administered by oral route demonstrated beneficial effects in preclinical models on glucose reduction, HbA1c reduction and showed an added benefit of weight loss. Additionally, ZYOG1 has displayed a differentiated preclinical safety profile with no nausea-like symptoms in the preclinical studies... [PDF] Zydus Cadila's Press Release -
